ZA201502073B - Pharmaceutical composition - Google Patents
Pharmaceutical compositionInfo
- Publication number
- ZA201502073B ZA201502073B ZA2015/02073A ZA201502073A ZA201502073B ZA 201502073 B ZA201502073 B ZA 201502073B ZA 2015/02073 A ZA2015/02073 A ZA 2015/02073A ZA 201502073 A ZA201502073 A ZA 201502073A ZA 201502073 B ZA201502073 B ZA 201502073B
- Authority
- ZA
- South Africa
- Prior art keywords
- pharmaceutical composition
- pharmaceutical
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1141MU2014 | 2014-03-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201502073B true ZA201502073B (en) | 2016-03-30 |
Family
ID=54194023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2015/02073A ZA201502073B (en) | 2014-03-28 | 2015-03-26 | Pharmaceutical composition |
Country Status (2)
| Country | Link |
|---|---|
| WO (1) | WO2015145157A1 (en) |
| ZA (1) | ZA201502073B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019053500A1 (en) | 2018-04-17 | 2019-03-21 | Alvogen Malta Operations (Row) Ltd | Pharmaceutical composition of solid dosage form containing pazopanib and process for its preparation |
| JP2023532126A (en) * | 2020-07-02 | 2023-07-26 | サムヤン ホールディングス コーポレイション | Tablet containing pazopanib as an active ingredient and method for producing the same |
| WO2022040446A1 (en) * | 2020-08-19 | 2022-02-24 | Nanocopoeia, Llc | Amorphous pazopanib particles and pharmaceutical compositions thereof |
| US20240075031A1 (en) * | 2020-12-07 | 2024-03-07 | Hht Foundation International, Inc. | Method of treating hereditary hemorrhagic telangiectasia using pazopanib |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013066616A1 (en) * | 2011-10-31 | 2013-05-10 | Glaxo Wellcome Manufacturing Pte Ltd | Pazopanib formulation |
| PL3181122T3 (en) * | 2012-01-13 | 2023-07-31 | Xspray Pharma Ab (Publ) | Dasatinib pharmaceutical composition |
-
2015
- 2015-03-26 WO PCT/GB2015/050902 patent/WO2015145157A1/en active Application Filing
- 2015-03-26 ZA ZA2015/02073A patent/ZA201502073B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015145157A1 (en) | 2015-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1225655A1 (en) | Pharmaceutical compositions comprising azd9291 | |
| GB201419257D0 (en) | Pharmaceutical compositions | |
| GB201618482D0 (en) | Pharmaceutical compositions | |
| GB201409471D0 (en) | Pharmaceutical composition | |
| IL249553A0 (en) | Pharmaceutical compositions | |
| GB201409488D0 (en) | Pharmaceutical composition | |
| SG11201605366QA (en) | Pharmaceutical composition containing pyridylaminoacetic acidcompound | |
| GB201409485D0 (en) | Pharmaceutical composition | |
| ZA201702086B (en) | Long acting pharmaceutical compositions | |
| GB201521462D0 (en) | Pharmaceutical composition | |
| ZA201508726B (en) | Pharmaceutical composition | |
| GB201515310D0 (en) | Pharmaceutical composition | |
| ZA201502073B (en) | Pharmaceutical composition | |
| IL250817A0 (en) | Pharmaceutical compositions | |
| GB201520862D0 (en) | Pharmaceutical composition | |
| SI3236952T1 (en) | Pharmaceutical tablet composition | |
| PT3200772T (en) | Pharmaceutical compositions comprising alpelisib | |
| SI3089740T1 (en) | Pharmaceutical composition | |
| SG11201608123VA (en) | Pharmaceutical composition for external use | |
| SG10201504332VA (en) | Pharmaceutical Composition | |
| SG11201608124XA (en) | Pharmaceutical composition for external use | |
| GB201521456D0 (en) | Pharmaceutical composition | |
| GB201516183D0 (en) | Novel pharmaceutical composition | |
| SG11201608122PA (en) | Pharmaceutical composition for external use | |
| SG2014014872A (en) | Pharmaceutical compositions |